FindTrial
Sign In

New cheaper human papilloma virus mass screening strategy reduces cervical cancer incidence in Changsha city: A clinical trial

New cheaper human papilloma virus mass screening strategy reduces cervical cancer incidence in Changsha city: A clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400090454
Enrollment
Unknown
Registered
2024-09-30
Start date
2019-01-09
Completion date
Unknown
Last updated
2024-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical carcinoma

Interventions

Case series:NA

Sponsors

Changsha Maternal and Child Health Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
35 Years to 64 Years

Inclusion criteria

Inclusion criteria: (1) Women aged 35-64 who have not participated in the national, provincial and municipal "two cancer" free examination from2019-2022, and have registered residence in Changsha or hold a residence permit in Changsha (the residence permit is within the validity period). (2) Individuals who are found to be positive for HPV16 and 18 through free "two cancer" testing in 2019-2022 are eligible to participate in the free "two cancer" testing for eligible women in Changsha in 2024.

Exclusion criteria

Exclusion criteria: Non Changsha household registration, women aged 35-64

Design outcomes

Primary

MeasureTime frame
HPV genotype;—

Countries

China

Contacts

Public ContactYue'e Zu

Changsha Maternal and Child Health Hospital

85042306@qq.com+86 139 7582 7868

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026